392 related articles for article (PubMed ID: 27772741)
1. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
Gaindh D; Kavak KS; Teter B; Vaughn CB; Cookfair D; Hahn T; Weinstock-Guttman B;
J Neurol Sci; 2016 Nov; 370():13-17. PubMed ID: 27772741
[TBL] [Abstract][Full Text] [Related]
2. Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients.
Chouhfeh L; Kavak KS; Teter BE; Weinstock-Guttman B
Mult Scler Relat Disord; 2015 May; 4(3):228-33. PubMed ID: 26008939
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
Jakimovski D; Kavak KS; Coyle PK; Goodman AD; Gottesman M; Zivadinov R; Weinstock-Guttman B;
J Neurol; 2024 Feb; 271(2):711-722. PubMed ID: 37995009
[TBL] [Abstract][Full Text] [Related]
4. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
[TBL] [Abstract][Full Text] [Related]
5. Cancer and multiple sclerosis in the era of disease-modifying treatments.
Lebrun C; Vermersch P; Brassat D; Defer G; Rumbach L; Clavelou P; Debouverie M; de Seze J; Wiertlevsky S; Heinzlef O; Tourbah A; Fromont A; Frenay M
J Neurol; 2011 Jul; 258(7):1304-11. PubMed ID: 21293872
[TBL] [Abstract][Full Text] [Related]
6. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
[TBL] [Abstract][Full Text] [Related]
7. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
8. Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register.
Lepore V; Paletta P; Bosetti C; Santucci C; Ponzio M; Pupillo E; Leone MA; Bergamaschi R; Mosconi P;
Mult Scler Relat Disord; 2024 Jul; 87():105638. PubMed ID: 38713966
[TBL] [Abstract][Full Text] [Related]
9. Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study.
Al-Sakran L; Marrie RA; Blackburn D; Knox K; Evans C
BMJ Open; 2019 Nov; 9(11):e033599. PubMed ID: 31772108
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).
Zivadinov R; Cookfair DL; Krupp L; Miller AE; Lava N; Coyle PK; Goodman AD; Jubelt B; Lenihan M; Herbert J; Gottesman M; Snyder DH; Apatoff BR; Teter BE; Perel AB; Munschauer F; Weinstock-Guttman B
BMC Neurol; 2016 Jul; 16():102. PubMed ID: 27416843
[TBL] [Abstract][Full Text] [Related]
11. Patient awareness about family planning represents a major knowledge gap in multiple sclerosis.
Rasmussen PV; Magyari M; Moberg JY; Bøgelund M; Jensen UFA; Madsen KG
Mult Scler Relat Disord; 2018 Aug; 24():129-134. PubMed ID: 30005355
[TBL] [Abstract][Full Text] [Related]
12. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
[TBL] [Abstract][Full Text] [Related]
13. Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60.
Hua LH; Harris H; Conway D; Thompson NR
Mult Scler Relat Disord; 2019 May; 30():252-256. PubMed ID: 30851638
[TBL] [Abstract][Full Text] [Related]
14. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
Higuera L; Carlin CS; Anderson S
J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
[TBL] [Abstract][Full Text] [Related]
15. Cancer risk, disease-modifying therapy, and age in multiple sclerosis: A retrospective population-based cohort study.
Greenfield J; Metz LM; Khakban A; Llorian ER; Michaux KD; Traboulsee A; Oh J; Smyth P; Lynd LD; Bulloch AGM; Williams JVA; Patten SB;
Mult Scler Relat Disord; 2023 Dec; 80():105091. PubMed ID: 37924714
[TBL] [Abstract][Full Text] [Related]
16. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
17. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
[TBL] [Abstract][Full Text] [Related]
18. Classifying PML risk with disease modifying therapies.
Berger JR
Mult Scler Relat Disord; 2017 Feb; 12():59-63. PubMed ID: 28283109
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Jakimovski D; Kavak KS; Vaughn CB; Goodman AD; Coyle PK; Krupp L; Gottesman M; Edwards KR; Lenihan M; Perel A; Zivadinov R; Weinstock-Guttman B;
Mult Scler Relat Disord; 2022 Jan; 57():103406. PubMed ID: 34915316
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Wiertlevski S; Defer G; Gout O; Berthier F; Danzon A
Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]